Cancer biotechs receive funding: Immunostep and Dp Pharma

, ,
Integral service around a transaction
BY : Diego GutiérrezMay Fri, 2016
In the last month we have heard about two Spanish companies that focus on the fight against cancer, Immunostep and Idp Pharma, which have received funding.


Immunostep receives €1.2M round from Altia capital

The company Salmantina Immunostep  was created at the University of Salamanca in 2007 and is dedicated to the development of reagents based on monoclonal antibodies for use in the diagnosis of human diseases, such as some cancers, using Flow Cytometry techniques.

Immunostep has received €1.2M from investors associated with the platform, also from Salamanca,  Alentia Capital Alternative.

The injection received will allow the development of the company's business plan for the coming years and avoids its possible delocalisation after the founding partners rejected a higher offer from a Chinese fund.

Alentia's investors have bought out the shares held by a Galician investment fund and a venture capital firm whose term in the company was coming to an end and who were interested in divesting. The exit of these funds endangered the stability of the company's capital, so the entry of Alentia's investors will allow the founding partners to enjoy a period of stability and focus on the company's business.

The investors who have entered the company highlight Immunostep's growth potential, which in the coming years will focus on the internationalisation of the company and the development of new biotech products.

Idp Pharma secures €1.4M investment

IDP Pharma is a biotech company located in Barcelona's science park that develops new therapies against cancer.

The company has received €1.4M from industrial investors and business angels.

The company will use the capital injection, among other things, to complete pre-clinical development of its two candidates for the treatment of multiple myeloma, a rare and incurable disease of the bone marrow and the second most common blood cancer.

Previously, it had obtained €575,000 of public funds from the CDTI, from the NEOTEC, of the Empresa Nacional de Innovación S.A. (ENISA), the Ministry of Economy and Competitiveness (MINECO) and the Generalitat de Catalunya's Acció agency.

These funds are in addition to the €100,000 raised in a first round closed in June 2015 with small investors, mainly scientists.

Other posts that may interest you

Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month

Investors lose their fear of investing in biotechnology

Spanish biotech companies go public

If you are looking for financing for your company, contact us. Abra-Invest has a team of experts in alternative financing at your disposal with extensive experience in the biotech sector. Call us on + 34 944240141 or fill in the contact form.



The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?